<p>Evercore 的研究分析师在周五发布的研究报告中开始覆盖 Biogen（纳斯达克代码：BIIB - 获取免费报告）的股票。该券商对这家生物技术公司的股票给予了 “跑赢大盘” 的评级。</p>
<ul>
<li>2026 年看起来像 “必胜” 赢家的 3 只生物技术股票</li>
</ul>
<p>BIIB 已经成为其他几份研究报告的主题。瑞穗证券将 Biogen 的目标股价从 207.00 美元上调至 236.00 美元，并在 2 月 10 日的研究报告中给予该公司 “跑赢大盘” 的评级。Stifel Nicolaus 将 Biogen 的目标股价从 202.00 美元上调至 214.00 美元，并在 2 月 6 日的报告中给予该公司 “买入” 评级。Canaccord Genuity Group 将 Biogen 的目标股价从 230.00 美元上调至 245.00 美元，并在 4 月 1 日的研究报告中给予该股票 “买入” 评级。华尔街 Zen 在 5 月 2 日的报告中将 Biogen 的评级从 “持有” 上调至 “买入”。最后，Tudor Pickering 在 2 月 9 日的研究报告中设定了 Biogen 的目标价为 201.00 美元。一位股票研究分析师给予该股票 “强烈买入” 评级，十四位分析师给予 “买入” 评级，十三位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Biogen 目前的平均评级为 “适度买入”，共识目标价为 214.65 美元。</p>
<p><strong>获取我们对 BIIB 的最新股票分析</strong></p>
<h2>Biogen 股票上涨 1.1%</h2>
<ul>
<li>Biogen 股票正在转变为价值投资</li>
</ul>
<p>周五，BIIB 股票上涨 2.04 美元，达到 193.41 美元。该公司的股票交易量为 73,762 股，而其平均交易量为 1,297,462 股。该公司的市值为 285.6 亿美元，市盈率为 20.68，市盈增长比率为 1.80，贝塔值为 0.19。Biogen 的 12 个月低点为 121.05 美元，12 个月高点为 205.97 美元。该公司的债务与股本比率为 0.34，速动比率为 2.41，流动比率为 3.06。该公司的 50 日移动平均价格为 185.15 美元，200 日移动平均价格为 179.24 美元。</p>
<p>Biogen（纳斯达克代码：BIIB - 获取免费报告）最近在 4 月 29 日宣布了其季度财报。这家生物技术公司报告的季度每股收益为 3.57 美元，超出分析师一致预期的 2.95 美元，超出幅度为 0.62 美元。该公司在本季度的收入为 24.8 亿美元，而分析师预期为 22.9 亿美元。Biogen 的股本回报率为 12.83%，净利润率为 13.81%。该公司的季度收入较去年同期增长了 1.9%。去年同期，该公司每股收益为 3.02 美元。Biogen 已将其 2026 财年的指导目标设定为每股收益 14.250-15.250 美元。平均而言，股票分析师预测 Biogen 在当前年度的每股收益为 14.21 美元。</p>
<h2>机构投资者对 Biogen 的看法</h2>
<ul>
<li>这 3 只股票被严重低估：抓住机会</li>
</ul>
<p>大型投资者最近买入和卖出了该公司的股票。Reflection Asset Management 在第四季度购买了 Biogen 的新股份，价值约 25,000 美元。WPG Advisers LLC 在第四季度将其在 Biogen 的持仓增加了 417.9%。WPG Advisers LLC 现在拥有 145 股该生物技术公司的股票，价值 26,000 美元，此前在该期间内又购买了 117 股。Accredited Wealth Management LLC 在第三季度将其在 Biogen 的持仓增加了 1,233.3%。Accredited Wealth Management LLC 现在拥有 200 股该生物技术公司的股票，价值 28,000 美元，此前在上个季度又购买了 185 股。First Horizon Corp 在第四季度收购了 Biogen 的新股份，价值约 30,000 美元。最后，WFA of San Diego LLC 在第二季度购买了 Biogen 的新股份，价值约 32,000 美元。目前 87.93% 的股票由机构投资者持有。</p>
<h2>Biogen 的关键新闻</h2>
<p>以下是本周影响 Biogen 的关键新闻：</p>
<ul>
<li>积极情绪：Biogen 报告了其阿尔茨海默病药物 <strong>diranersen (BIIB080)</strong> 的二期顶线数据，显示出显著减少 tau 病理和认知衰退减缓的信号，该公司表示将推进该项目进入三期/注册开发。文章标题</li>
<li>积极情绪：投资者也欢迎 Biogen 完成 <strong>53 亿美元的 Apellis Pharmaceuticals 收购</strong>，该收购增加了商业产品 <strong>SYFOVRE</strong> 和 <strong>EMPAVELI</strong>，可能增强近期增长。文章标题</li>
<li>中性情绪：几位分析师在数据发布后维持了 <strong>持有</strong> 评级，认为数据存在混合：生物标志物和认知信号令人鼓舞，但研究 <strong>未能达到其主要终点</strong>。文章标题</li>
<li>消极情绪：阿尔茨海默病研究的失败使得 diranersen 能否迅速转化为商业价值存在一些不确定性，而 Apellis 交易增加了整合和融资的考虑。文章标题</li>
</ul>
<h2>关于 Biogen</h2>
<p>（获取免费报告）</p>
<p>Biogen Inc 是一家跨国生物技术公司，专注于发现、开发和提供神经和神经退行性疾病的治疗方案。公司总部位于马萨诸塞州剑桥，长期以来专注于神经科学，研究和商业活动涵盖多种治疗领域，包括多发性硬化症、脊髓性肌萎缩症和阿尔茨海默病。Biogen 成立于 1978 年，已发展成为一家全球生物制药公司，在北美、欧洲、日本及其他国际市场拥有业务和商业存在。</p>
<p>该公司的市场产品组合历史上包括几种知名的多发性硬化症治疗药物，如 Avonex、Tysabri 和 Tecfidera，并且它还在追求针对罕见神经疾病和遗传性神经肌肉疾病的治疗。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，胜过 Biogen</li>
<li>3 只值得关注的 AI 数据中心股票，适合资本轮动</li>
<li>麦当劳的价格是多年来最低——这是否意味着值得购买？</li>
<li>Karman：国防明星在经历 40% 下跌后前景增强</li>
<li>Aeluma 的财报后下跌创造了买入机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Biogen 吗？</h2>
<p>在考虑 Biogen 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Biogen 并不在名单上。</p>
<p>虽然 Biogen 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BIIB

IBBQ

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

<p>Evercore 已经开始对 Biogen (NASDAQ:BIIB) 进行覆盖，给予其 “跑赢大盘” 的评级。其他分析师也提高了他们的目标价，其中瑞穗证券将其提高至 236.00 美元。Biogen 的股价上涨了 1.1%，达到 193.41 美元，市值为 285.6 亿美元。该公司报告了强劲的季度收益，超出预期，并将 2026 财年的每股收益指导设定在 14.250-15.250。机构投资者持有 87.93% 的股份</p>

<p>Research analysts at Evercore began coverage on shares of Biogen (NASDAQ:BIIB - Get Free Report) in a research report issued on Friday. The brokerage set an &#34;outperform&#34; rating on the biotechnology company's stock.</p>
<div class="lb-trans"><p>Evercore 的研究分析师在周五发布的研究报告中开始覆盖 Biogen（纳斯达克代码：BIIB - 获取免费报告）的股票。该券商对这家生物技术公司的股票给予了 “跑赢大盘” 的评级。</p>
</div><ul>
<li>3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>2026 年看起来像 “必胜” 赢家的 3 只生物技术股票</li>
</ul>
</div><p>BIIB has been the topic of several other research reports. Mizuho upped their price objective on shares of Biogen from $207.00 to $236.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday, February 10th. Stifel Nicolaus boosted their price target on shares of Biogen from $202.00 to $214.00 and gave the company a &#34;buy&#34; rating in a report on Friday, February 6th. Canaccord Genuity Group upped their price target on shares of Biogen from $230.00 to $245.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, April 1st. Wall Street Zen upgraded Biogen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, May 2nd. Finally, Tudor Pickering set a $201.00 target price on Biogen in a research note on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Biogen presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $214.65.</p>
<div class="lb-trans"><p>BIIB 已经成为其他几份研究报告的主题。瑞穗证券将 Biogen 的目标股价从 207.00 美元上调至 236.00 美元，并在 2 月 10 日的研究报告中给予该公司 “跑赢大盘” 的评级。Stifel Nicolaus 将 Biogen 的目标股价从 202.00 美元上调至 214.00 美元，并在 2 月 6 日的报告中给予该公司 “买入” 评级。Canaccord Genuity Group 将 Biogen 的目标股价从 230.00 美元上调至 245.00 美元，并在 4 月 1 日的研究报告中给予该股票 “买入” 评级。华尔街 Zen 在 5 月 2 日的报告中将 Biogen 的评级从 “持有” 上调至 “买入”。最后，Tudor Pickering 在 2 月 9 日的研究报告中设定了 Biogen 的目标价为 201.00 美元。一位股票研究分析师给予该股票 “强烈买入” 评级，十四位分析师给予 “买入” 评级，十三位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Biogen 目前的平均评级为 “适度买入”，共识目标价为 214.65 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on BIIB</strong></p>
<div class="lb-trans"><p><strong>获取我们对 BIIB 的最新股票分析</strong></p>
</div><h2>Biogen Stock Up 1.1%</h2>
<div class="lb-trans"><h2>Biogen 股票上涨 1.1%</h2>
</div><ul>
<li>Biogen Stock Is Mutating Into a Value Play</li>
</ul>
<div class="lb-trans"><ul>
<li>Biogen 股票正在转变为价值投资</li>
</ul>
</div><p>Shares of BIIB stock traded up $2.04 on Friday, reaching $193.41. 73,762 shares of the company's stock traded hands, compared to its average volume of 1,297,462. The company has a market capitalization of $28.56 billion, a P/E ratio of 20.68, a price-to-earnings-growth ratio of 1.80 and a beta of 0.19. Biogen has a 12-month low of $121.05 and a 12-month high of $205.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The business's 50 day moving average price is $185.15 and its two-hundred day moving average price is $179.24.</p>
<div class="lb-trans"><p>周五，BIIB 股票上涨 2.04 美元，达到 193.41 美元。该公司的股票交易量为 73,762 股，而其平均交易量为 1,297,462 股。该公司的市值为 285.6 亿美元，市盈率为 20.68，市盈增长比率为 1.80，贝塔值为 0.19。Biogen 的 12 个月低点为 121.05 美元，12 个月高点为 205.97 美元。该公司的债务与股本比率为 0.34，速动比率为 2.41，流动比率为 3.06。该公司的 50 日移动平均价格为 185.15 美元，200 日移动平均价格为 179.24 美元。</p>
</div><p>Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping analysts' consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business's quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the company posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities analysts forecast that Biogen will post 14.21 earnings per share for the current year.</p>
<div class="lb-trans"><p>Biogen（纳斯达克代码：BIIB - 获取免费报告）最近在 4 月 29 日宣布了其季度财报。这家生物技术公司报告的季度每股收益为 3.57 美元，超出分析师一致预期的 2.95 美元，超出幅度为 0.62 美元。该公司在本季度的收入为 24.8 亿美元，而分析师预期为 22.9 亿美元。Biogen 的股本回报率为 12.83%，净利润率为 13.81%。该公司的季度收入较去年同期增长了 1.9%。去年同期，该公司每股收益为 3.02 美元。Biogen 已将其 2026 财年的指导目标设定为每股收益 14.250-15.250 美元。平均而言，股票分析师预测 Biogen 在当前年度的每股收益为 14.21 美元。</p>
</div><h2>Institutional Investors Weigh In On Biogen</h2>
<div class="lb-trans"><h2>机构投资者对 Biogen 的看法</h2>
</div><ul>
<li>These 3 Stocks Are Screaming Oversold: Seize the Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>这 3 只股票被严重低估：抓住机会</li>
</ul>
</div><p>Large investors have recently bought and sold shares of the business. Reflection Asset Management bought a new stake in shares of Biogen during the 4th quarter worth about $25,000. WPG Advisers LLC boosted its position in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company's stock worth $26,000 after purchasing an additional 117 shares during the period. Accredited Wealth Management LLC grew its holdings in Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 185 shares during the last quarter. First Horizon Corp acquired a new position in Biogen during the fourth quarter valued at approximately $30,000. Finally, WFA of San Diego LLC bought a new position in shares of Biogen in the second quarter valued at approximately $32,000. 87.93% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。Reflection Asset Management 在第四季度购买了 Biogen 的新股份，价值约 25,000 美元。WPG Advisers LLC 在第四季度将其在 Biogen 的持仓增加了 417.9%。WPG Advisers LLC 现在拥有 145 股该生物技术公司的股票，价值 26,000 美元，此前在该期间内又购买了 117 股。Accredited Wealth Management LLC 在第三季度将其在 Biogen 的持仓增加了 1,233.3%。Accredited Wealth Management LLC 现在拥有 200 股该生物技术公司的股票，价值 28,000 美元，此前在上个季度又购买了 185 股。First Horizon Corp 在第四季度收购了 Biogen 的新股份，价值约 30,000 美元。最后，WFA of San Diego LLC 在第二季度购买了 Biogen 的新股份，价值约 32,000 美元。目前 87.93% 的股票由机构投资者持有。</p>
</div><h2>Key Biogen News</h2>
<div class="lb-trans"><h2>Biogen 的关键新闻</h2>
</div><p>Here are the key news stories impacting Biogen this week:</p>
<div class="lb-trans"><p>以下是本周影响 Biogen 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Biogen reported topline Phase 2 data for its Alzheimer’s drug <strong>diranersen (BIIB080)</strong> showing robust reductions in tau pathology and signals of slower cognitive decline, and the company said it will advance the program into Phase 3/registrational development. Article Title</li>
<li>Positive Sentiment: Investors also welcomed the completion of Biogen’s <strong>$5.3 billion Apellis Pharmaceuticals acquisition</strong>, which adds commercial products <strong>SYFOVRE</strong> and <strong>EMPAVELI</strong> and could strengthen near-term growth. Article Title</li>
<li>Neutral Sentiment: Several analysts maintained <strong>Hold</strong> ratings after the readout, arguing the data were mixed: biomarker and cognitive signals were encouraging, but the study <strong>missed its primary endpoint</strong>. Article Title</li>
<li>Negative Sentiment: The Alzheimer’s study failure leaves some uncertainty around how quickly diranersen can translate into commercial value, and the Apellis deal adds integration and financing considerations. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Biogen 报告了其阿尔茨海默病药物 <strong>diranersen (BIIB080)</strong> 的二期顶线数据，显示出显著减少 tau 病理和认知衰退减缓的信号，该公司表示将推进该项目进入三期/注册开发。文章标题</li>
<li>积极情绪：投资者也欢迎 Biogen 完成 <strong>53 亿美元的 Apellis Pharmaceuticals 收购</strong>，该收购增加了商业产品 <strong>SYFOVRE</strong> 和 <strong>EMPAVELI</strong>，可能增强近期增长。文章标题</li>
<li>中性情绪：几位分析师在数据发布后维持了 <strong>持有</strong> 评级，认为数据存在混合：生物标志物和认知信号令人鼓舞，但研究 <strong>未能达到其主要终点</strong>。文章标题</li>
<li>消极情绪：阿尔茨海默病研究的失败使得 diranersen 能否迅速转化为商业价值存在一些不确定性，而 Apellis 交易增加了整合和融资的考虑。文章标题</li>
</ul>
</div><h2>About Biogen</h2>
<div class="lb-trans"><h2>关于 Biogen</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.</p>
<div class="lb-trans"><p>Biogen Inc 是一家跨国生物技术公司，专注于发现、开发和提供神经和神经退行性疾病的治疗方案。公司总部位于马萨诸塞州剑桥，长期以来专注于神经科学，研究和商业活动涵盖多种治疗领域，包括多发性硬化症、脊髓性肌萎缩症和阿尔茨海默病。Biogen 成立于 1978 年，已发展成为一家全球生物制药公司，在北美、欧洲、日本及其他国际市场拥有业务和商业存在。</p>
</div><p>The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.</p>
<div class="lb-trans"><p>该公司的市场产品组合历史上包括几种知名的多发性硬化症治疗药物，如 Avonex、Tysabri 和 Tecfidera，并且它还在追求针对罕见神经疾病和遗传性神经肌肉疾病的治疗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Biogen</li>
<li>3 AI Data Center Stocks Worth Watching for Capital Rotation</li>
<li>McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy?</li>
<li>Karman: Defense Darling's Outlook Strengthens After 40% Drop</li>
<li>Aeluma's Post-Earnings Dip Creates a Buying Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Biogen</li>
<li>3 只值得关注的 AI 数据中心股票，适合资本轮动</li>
<li>麦当劳的价格是多年来最低——这是否意味着值得购买？</li>
<li>Karman：国防明星在经历 40% 下跌后前景增强</li>
<li>Aeluma 的财报后下跌创造了买入机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BIIB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Biogen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Biogen 吗？</h2>
</div><p>Before you consider Biogen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Biogen 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Biogen 并不在名单上。</p>
</div><p>While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Biogen 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Biogen（纳斯达克股票代码：BIIB）现已被 Evercore 覆盖